Denmark· DK-28107026923
Dazparda
A insulin aspart product containing insulin aspart, registered in Denmark by Gan & Lee Pharmaceuticals Europe GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Insulin aspart is registered in 11 of 19 countries.
Countries holding a registration under ATC A10AB05 (insulin aspart), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Insulin aspart · ATC A10AB05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Insulin aspart
- Manufacturer
- Gan & Lee Pharmaceuticals Europe GmbH
- Country
- Denmark (DK)
- ATC code
- A10AB05
- ATC class
- Insulin aspart
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107026923
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
434 interactions on record for insulin aspart.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin aspart · interactions on record
434 records
- 15 severe
- 368 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10AB05
Insulin aspart, as other registers publish it.
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- NetherlandsDazparda 100 eenheden/ml oplossing voor injectie in een voorgevulde penGan & Lee Pharmaceuticals Europe GmbH
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- IrelandDazparda 100 units/ml solution for injection in pre-filled penGan & Lee Pharmaceuticals Europe GmbH
- FinlandFiaspNovo Nordisk A/S
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/31dc9361-5564-463e-91ae-7678f5e250a9 GET /v1/drugs/31dc9361-5564-463e-91ae-7678f5e250a9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt pen",
"source": "dkma",
"strength": "100 enheder/ml",
"auth_role": "RAP",
"dk_drugid": "28107026923",
"substance": "Insulin aspart",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "46139"
}See everything about insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.